Literature DB >> 35040782

The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinoma.

Qing Yang1, Changfeng Sun1, Yunjian Sheng1, Wen Chen1, Cunliang Deng1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and more than half of the newly diagnosed cases are chronic hepatitis B patients. Due to the lack of specific clinical manifestations, many patients are already at an advanced stage at the time of diagnosis and therefore have missed the best time for treatment. Organs in a pathological state usually secrete specific substances into the blood, which can indirectly indicate the pathological state of the organ, so some biological markers in the blood can be used as a tool to predict the incidence of HCC.
METHODS: The Research articles related to HCC were collected by searching PubMed databases with the keywords "hepatocellular carcinoma", "serum biomarker", "hepatitis B", "prediction" and "prognosis", and Additional articles were identified by manual search of references found in the primary articles, followed by a summary and review.
RESULTS: Viral hepatitis is the main cause of HCC worldwide, and this phenomenon is particularly prominent in Asian and African populations. A variety of serological markers including M2BPGi, IL-6 and COMP can be used to predict the incidence of long-term HCC in patients. The risk of HCC is dynamic rather than constant, and dynamic detection will help improve prediction accuracy. For hepatitis B patients, HBV DNA load and HBcr Ag are important predictive markers of HCC.
CONCLUSION: For a high-risk population of HCC, early risk prediction is helpful to guide clinical work, and timely adjustments of the screening frequency and treatment plan are helpful to prolong the survival time of HCC patients.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35040782      PMCID: PMC9128464          DOI: 10.5152/tjg.2022.19813

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  50 in total

1.  Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.

Authors:  Nehal Elmashad; Wesam Salah Ibrahim; Wael Wahid Mayah; Mohamed Farouk; Lobna Abo Ali; Atef Taha; Wael Elmashad
Journal:  Asian Pac J Cancer Prev       Date:  2015

2.  Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.

Authors:  James Fung; Ka-Shing Cheung; Danny Ka-Ho Wong; Lung-Yi Mak; Wai-Pan To; Wai-Kay Seto; Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatology       Date:  2018-06-06       Impact factor: 17.425

3.  Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.

Authors:  Danny Ka-Ho Wong; Wai-Kay Seto; Ka-Shing Cheung; Chun-Kong Chong; Fung-Yu Huang; James Fung; Ching-Lung Lai; Man-Fung Yuen
Journal:  Liver Int       Date:  2017-01-28       Impact factor: 5.828

4.  Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells.

Authors:  Shupeng Liu; Nan Li; Xiya Yu; Xiao Xiao; Kai Cheng; Jingjing Hu; Jiaqi Wang; Dandan Zhang; Shuqun Cheng; Shanrong Liu
Journal:  Gastroenterology       Date:  2013-01-31       Impact factor: 22.682

5.  High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.

Authors:  Fabian Finkelmeier; Özge Canli; Andrea Tal; Thomas Pleli; Jörg Trojan; Michael Schmidt; Bernd Kronenberger; Stefan Zeuzem; Albrecht Piiper; Florian R Greten; Oliver Waidmann
Journal:  Eur J Cancer       Date:  2016-03-31       Impact factor: 9.162

6.  The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study.

Authors:  Yi Liu; Xiwei Wang; Sanglin Li; Huaidong Hu; Dazhi Zhang; Peng Hu; Yixuan Yang; Hong Ren
Journal:  J Proteomics       Date:  2014-04-24       Impact factor: 4.044

7.  Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice.

Authors:  Lingxiang Kong; Yongjie Zhou; Hong Bu; Tao Lv; Yujun Shi; Jiayin Yang
Journal:  J Exp Clin Cancer Res       Date:  2016-09-02

8.  von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.

Authors:  Hiroaki Takaya; Hideto Kawaratani; Yuki Tsuji; Keisuke Nakanishi; Soichiro Saikawa; Shinya Sato; Yasuhiko Sawada; Kosuke Kaji; Yasushi Okura; Naotaka Shimozato; Mitsuteru Kitade; Takemi Akahane; Kei Moriya; Tadashi Namisaki; Akira Mitoro; Masanori Matsumoto; Hiroshi Fukui; Hitoshi Yoshiji
Journal:  United European Gastroenterol J       Date:  2018-05-25       Impact factor: 4.623

9.  Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.

Authors:  Talita Duarte-Salles; Sandeep Misra; Magdalena Stepien; Amelie Plymoth; David Muller; Kim Overvad; Anja Olsen; Anne Tjønneland; Laura Baglietto; Gianluca Severi; Marie-Christine Boutron-Ruault; Renee Turzanski-Fortner; Rudolf Kaaks; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Pagona Lagiou; Christina Bamia; Valeria Pala; Domenico Palli; Amalia Mattiello; Rosario Tumino; Alessio Naccarati; H B As Bueno-de-Mesquita; Petra H Peeters; Elisabete Weiderpass; J Ramón Quirós; Antonio Agudo; Emilio Sánchez-Cantalejo; Eva Ardanaz; Diana Gavrila; Miren Dorronsoro; Mårten Werner; Oskar Hemmingsson; Bodil Ohlsson; Klas Sjöberg; Nicholas J Wareham; Kay-Tee Khaw; Kathryn E Bradbury; Marc J Gunter; Amanda J Cross; Elio Riboli; Mazda Jenab; Pierre Hainaut; Laura Beretta
Journal:  Cancer Prev Res (Phila)       Date:  2016-06-23

10.  Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.

Authors:  Yu-Ju Lin; Mei-Hsuan Lee; Hwai-I Yang; Chin-Lan Jen; San-Lin You; Li-Yu Wang; Sheng-Nan Lu; Jessica Liu; Chien-Jen Chen
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.